ATM (Ataxia-Telangiectasia Mutated kinase)
The master sensor kinase for DNA double-strand breaks (DSBs) — a 3,056-amino-acid serine/threonine kinase of the PIKK (PI3K-like kinase) superfamily that phosphorylates >700 substrates to coordinate the entire DNA damage response (DDR). Biallelic loss-of-function mutations cause ataxia-telangiectasia (AT), a progeroid syndrome with cerebellar degeneration, immunodeficiency, radiosensitivity, cancer predisposition, and multiple accelerated-aging features. ATM is a direct mechanistic bridge between genomic-instability accumulation and cellular-senescence induction via the SASP.
Identity
- UniProt: Q13315 (ATM_HUMAN) — Swiss-Prot (manually curated)
- NCBI Gene: 472
- HGNC symbol: ATM (HGNC: 795)
- Ensembl: ENSG00000149311
- Mouse ortholog: Atm (one-to-one ortholog; functionally conserved)
- Length: 3,056 amino acids (~370 kDa)
- Chromosome: 11q22.3
Key functional domains
ATM’s domain architecture is conserved across PIKK family members (mTOR, ATR, DNA-PKcs, TRRAP):
- N-terminal HEAT repeats (residues ~1–1939) — ~40 tandem HEAT (Huntingtin, Elongation factor 3, PR65/A, TOR) repeats forming a large curved solenoid scaffold that mediates protein-protein interactions, particularly with the MRN complex (MRE11-RAD50-NBS1)
- FAT domain (residues 1940–2566) — Found in FRAP, ATM, TRRAP; wraps back around the kinase domain and is required for full activation
- PI3K/PI4K catalytic (kinase) domain (residues 2686–2998) — Serine/threonine kinase; recognizes the consensus [S/T]-Q motif on substrates; structurally similar to lipid PI3-kinases but acts exclusively on protein substrates
- FATC domain (residues 3024–3056) — ~30-residue C-terminal domain common to all PIKKs; required for kinase activity; acetylation of Lys3016 by TIP60/KAT5 within this region is a prerequisite for full ATM activation
Activation mechanism
Under non-stressed conditions, ATM exists as an inactive dimer or higher-order multimer in the nucleus; the Ser1981-containing region (in the FAT domain) interacts with the kinase domain of the opposing monomer, keeping it inactive 1.
Upon DSB induction, activation proceeds in two coordinated steps:
- MRN complex recruitment — MRE11-RAD50-NBS1 (MRN) binds DSB ends and directly contacts ATM’s HEAT repeat scaffold via NBS1’s C-terminus, tethering ATM to the break site.
- Autophosphorylation and dimer dissociation — ATM undergoes intermolecular autophosphorylation at Ser1981 (within the FAT domain), which is sufficient and required for dimer dissociation into catalytically active monomers 1. Additional autophosphorylation at Ser367 and Ser1893 follows. TIP60/KAT5 acetylation of Lys3016 also contributes to full activation by stabilizing the active conformation.
Active monomeric ATM then spreads along the chromatin flanking the break (anchored partly via ÎłH2AX-MDC1 scaffolding) and phosphorylates hundreds of substrates bearing the [S/T]-Q consensus. Dephosphorylation at Ser1981 by phosphatases (including PP2A family members) terminates the DDR signal during late-stage repair.
A cytoplasmic pool of ATM also exists — it responds to oxidative stress (ROS) and translocates to peroxisomes via PEX5, suggesting DDR-independent functions 2.
Key substrates
ATM phosphorylates >700 proteins at [S/T]-Q sites 3. The aging-relevant major substrates:
| Substrate | Site | Immediate consequence | Downstream outcome |
|---|---|---|---|
| p53 | Ser15 | Disrupts MDM2 binding; stabilizes p53 | Cell cycle arrest, senescence, apoptosis |
| mdm2 | Ser395 | Disrupts MDM2–p53 interaction independently | Reinforces p53 stabilization |
| CHK2 | Thr68 | CHK2 autophosphorylation and activation | G1/S and G2/M checkpoint enforcement |
| H2AX | Ser139 (→ γH2AX) | Histone mark; MDC1 scaffold recruitment | DSB repair complex assembly |
| BRCA1 | Ser1387, Ser1524 | BRCA1 activation | HR pathway engagement |
| NBS1 | Ser343 | NBS1 modification; amplifies MRN signal | Sustained ATM retention at DSBs |
| SMC1 | Ser957, Ser966 | SMC1 (cohesin) modification | S-phase checkpoint, sister chromatid cohesion |
The p53 Ser15 phosphorylation is particularly relevant to aging: it stabilizes p53 and licenses it to induce senescence programs and, via transcriptional activation of SASP-driving genes, contribute to chronic tissue inflammation 4.
Pathway membership
- dna-damage-response — ATM is the apical kinase of the DSB-response branch; ATR handles single-stranded breaks / replication stress
- p53-pathway — ATM→p53(Ser15) + ATM→MDM2(Ser395) are the canonical DDR→p53 activation routes
- cell-cycle-checkpoint — via CHK2 (G1/S and G2/M) and directly via CDC25A/B/C phosphorylation
- cellular-senescence — persistent ATM signaling (unable to be resolved by repair) converts transient arrest into permanent senescence and SASP induction
Role in aging
Ataxia-telangiectasia: a progeroid syndrome
Biallelic loss-of-function ATM mutations (autosomal recessive; ~1/100,000 births) cause AT, a multi-system progeroid syndrome 5:
- Cerebellar ataxia — progressive Purkinje cell degeneration; onset in infancy; wheelchair-bound by adolescence
- Telangiectasias — conjunctival and facial vascular dilation
- Immunodeficiency — thymic hypoplasia, low IgA/IgE; recurrent respiratory infections
- Radiosensitivity — >1000-fold increased sensitivity to ionizing radiation
- Cancer predisposition — ~30% develop malignancies (predominantly lymphomas/leukemias)
- Accelerated aging features — premature graying, endocrine abnormalities, insulin resistance, accelerated telomere shortening
- Lifespan: median survival ~25 years (primarily from cancer and respiratory infection) — figure cited from Shiloh & Ziv 2013 review (closed-access; not verified against full text) no-fulltext-access
The progeroid features of AT — occurring in the absence of ATM-mediated DSB repair — directly illustrate how unresolved genomic instability drives systemic aging.
| Dimension | Status | Notes |
|---|---|---|
| Pathway conserved in humans? | yes | ATM gene, PIKK structure, and [S/T]-Q phosphorylation are conserved across vertebrates; Atm-knockout mice phenocopy AT |
| Phenotype (progeroid) in humans? | yes | Human AT patients are the disease model; not extrapolation |
| Mechanism (DSB → aging) in humans? | yes (genetics) | Biallelic ATM loss = AT; heterozygotes show intermediate phenotypes |
AT heterozygotes and population-level aging risk
ATM heterozygotes (~1% of the general population) have a ~2–4-fold elevated breast cancer risk — the best-established intermediate phenotype 2. (Prevalence and risk figures cited from Shiloh & Ziv 2013 review; full PDF closed-access.) no-fulltext-access Epidemiological signals of accelerated aging in ATM carriers exist but are weaker and inconsistent. needs-replication
Progressive ATM activity decline with age
ATM signaling efficiency appears to decline with aging in multiple tissues, contributing to impaired DSB repair and the accumulation of genomic-instability observed in aged cells. The mechanism is not fully established — candidate explanations include reduced ATM expression, chromatin remodeling reducing accessibility, and altered MRN complex dynamics. no-mechanism needs-human-replication
ATM is required for the inflammatory subset of SASP: the DDR→senescence→inflammation axis
A critical aging-biology function of ATM is its requirement for the major inflammatory components of the senescence-associated secretory phenotype (SASP) — specifically the pro-inflammatory cytokines IL-6 and IL-8, but not all SASP factors 4. Key findings:
- ATM depletion (shRNA) in genotoxin-induced senescent cells suppresses a subset of SASP factors — IL-6 secretion is reduced ~50-fold and IL-8 ~10-fold — without reversing cell-cycle arrest; nine other SASP factors are ATM-independent 4 needs-replication
- This positions ATM upstream of NF-κB activation in the chronic DDR→SASP axis
- Implication for aging: tissue-resident senescent cells accumulating with age require sustained ATM activity to maintain their pro-inflammatory secretome, making ATM a potential indirect driver of inflammaging and paracrine senescence propagation
| Dimension | Status | Notes |
|---|---|---|
| DDR→SASP mechanism in humans? | partial | SASP observed in human senescent cells; ATM requirement shown in culture; in-vivo human validation lacking |
| Replicated? | partial | Multiple labs confirmed SASP-DDR coupling; ATM-specific requirement needs more replication |
| Relevant to in-vivo aging? | unknown | needs-human-replication |
Pharmacology
ATM inhibitors (research tools and oncology investigationals)
| Compound | Class | Status | Notes |
|---|---|---|---|
| KU-55933 | ATP-competitive small molecule | Research tool | First selective ATM inhibitor; poor in-vivo pharmacokinetics |
| KU-60019 | Improved KU-55933 analog | Research tool | Better CNS penetration; used in radiosensitization studies |
| AZD0156 | Clinical-stage ATM inhibitor | Phase I (oncology) | AstraZeneca; combined with olaparib or irinotecan in HR-deficient tumors |
| M3541 | Clinical-stage ATM inhibitor | Phase I (oncology) | Merck KGaA; radiosensitizer |
Aging relevance of ATM inhibitors: In the aging context, ATM inhibition is primarily studied as a tool to dissect the DDR→SASP axis, not as a therapeutic strategy. Inhibiting ATM in aged organisms would be expected to worsen genomic instability and accelerate AT-like pathology. There is no aging-relevant ATM-activating clinical drug. unsourced — the therapeutic hypothesis of partial ATM modulation in aging remains speculative.
Note: The conceptual target for aging intervention may be downstream of ATM (e.g., SASP mediators such as NF-ÎşB, or senolytic clearance of SASP-secreting cells) rather than ATM itself.
Limitations and extrapolation gaps
| Gap | Tag | Notes |
|---|---|---|
| In-vivo human data on ATM activity decline with age | needs-human-replication | Most evidence is from cell culture or AT patient tissue |
| ATM-specific requirement for inflammatory SASP in vivo | needs-replication | Rodier 2009 showed ATM depletion reduces IL-6 ~50-fold and IL-8 ~10-fold in culture (HCA2 fibroblasts); nine of 16 surveyed SASP factors were ATM-independent; in-vivo genetic confirmation in animals or humans lacking |
| AT heterozygote aging phenotypes | needs-replication | Epidemiological data conflicting |
| ATM function in aging beyond DDR | no-mechanism | Cytoplasmic/peroxisomal ATM roles in ROS sensing are poorly characterized in aging context |
| Therapeutic window for ATM modulation in aging | unsourced | No preclinical aging-extension data |
Footnotes
Footnotes
-
doi:10.1038/nature01368 · Bakkenist & Kastan 2003 · in-vitro + in-vivo · model: human cells (IR-treated) · discovery of Ser1981 autophosphorylation and dimer→monomer activation mechanism · n=3394 citations (Nature) ↩ ↩2
-
doi:10.1038/nrm3546 · Shiloh & Ziv 2013 · review · “The ATM protein kinase: regulating the cellular response to genotoxic stress, and more” · Nat Rev Mol Cell Biol · comprehensive review of ATM biology and AT · PDF not available (not_oa per a local paper archive); quantitative claims (lifespan ~25 y, heterozygote prevalence ~1%, breast cancer risk ~2–4-fold) not verified against full text no-fulltext-access ↩ ↩2
-
doi:10.1126/science.1140321 · Matsuoka et al. 2007 · in-vitro + phosphoproteomics · model: human cells (IR-treated) · “ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage” · Science · identified >900 regulated phosphorylation sites across >700 ATM/ATR substrate proteins (abstract-confirmed via Crossref) · PDF not available (not_oa per a local paper archive); individual substrate sites (p53 Ser15, MDM2 Ser395, CHK2 Thr68, H2AX Ser139) not verified against full text no-fulltext-access ↩
-
doi:10.1038/ncb1909 · Rodier et al. 2009 · in-vitro · model: human HCA2 foreskin fibroblasts (primary); WI-38 fibroblasts (secondary) · “Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion” · Nat Cell Biol · ATM depletion (80–90%) reduced IL-6 ~50-fold and IL-8 ~10-fold in senescent cells; ATM required for a subset of SASP factors (major inflammatory cytokines) but not all 16 factors surveyed; DDR-independent senescence (p16^INK4a) does not trigger the cytokine response ↩ ↩2 ↩3
-
doi:10.1126/science.7792600 · Savitsky et al. 1995 · discovery paper · “A Single Ataxia Telangiectasia Gene with a Product Similar to PI-3 Kinase” · Science · original cloning of ATM gene; identified on chromosome 11q22-23 (modern annotation: 11q22.3) · PDF not available (not_oa per a local paper archive); verified via Crossref abstract no-fulltext-access ↩